Jack Allen
Stock Analyst
(2.06)
# 4,648
Out of 4,648 analysts
38
Total ratings
38.71%
Success rate
-2.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $15.14 | +18.89% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $27.63 | +551.47% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $7 → $6 | $0.46 | +1,195.90% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $4.01 | +99.50% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $50.59 | +2.79% | 2 | May 9, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $63 → $77 | $86.44 | -10.92% | 4 | Feb 29, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $31.17 | +169.49% | 1 | Oct 31, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $6 → $8 | $1.34 | +497.01% | 4 | Aug 15, 2023 | |
| CARM Carisma Therapeutics | Reiterates: Outperform | $10 | $1.05 | +852.38% | 2 | Jun 28, 2023 | |
| VOR Vor Biopharma | Maintains: Outperform | $38 → $22 | $0.78 | +2,720.51% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $3.00 | +300.00% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.84 | +496.23% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $2.76 | +914.49% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.76 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $0.73 | +3,466.53% | 1 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $6.65 | +35.34% | 1 | Oct 7, 2021 |
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $15.14
Upside: +18.89%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $27.63
Upside: +551.47%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $7 → $6
Current: $0.46
Upside: +1,195.90%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $4.01
Upside: +99.50%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $50.59
Upside: +2.79%
Arcellx
Feb 29, 2024
Maintains: Outperform
Price Target: $63 → $77
Current: $86.44
Upside: -10.92%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $31.17
Upside: +169.49%
Taysha Gene Therapies
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $1.34
Upside: +497.01%
Carisma Therapeutics
Jun 28, 2023
Reiterates: Outperform
Price Target: $10
Current: $1.05
Upside: +852.38%
Vor Biopharma
Mar 24, 2023
Maintains: Outperform
Price Target: $38 → $22
Current: $0.78
Upside: +2,720.51%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $3.00
Upside: +300.00%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.84
Upside: +496.23%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $2.76
Upside: +914.49%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.76
Upside: -
Nov 9, 2021
Initiates: Outperform
Price Target: $26
Current: $0.73
Upside: +3,466.53%
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $6.65
Upside: +35.34%